Research output: Contribution to journal › Article › peer-review
Effect of Poly(L-lysine) and Heparin Coatings on the Surface of Polyester-Based Particles on Prednisolone Release and Biocompatibility. / Mohamed , Abdelrahman ; Korzhikov-Vlakh, Viktor ; Zhang, Nan; Said, Andre; Pilipenko, Iuliia ; Schäfer-Korting, Monika; Zoschke, Christian ; Tennikova, Tatiana .
In: Pharmaceutics, Vol. 13, No. 6, 801, 06.2021.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Effect of Poly(L-lysine) and Heparin Coatings on the Surface of Polyester-Based Particles on Prednisolone Release and Biocompatibility
AU - Mohamed , Abdelrahman
AU - Korzhikov-Vlakh, Viktor
AU - Zhang, Nan
AU - Said, Andre
AU - Pilipenko, Iuliia
AU - Schäfer-Korting, Monika
AU - Zoschke, Christian
AU - Tennikova, Tatiana
N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/6
Y1 - 2021/6
N2 - A plethora of micro- and nanoparticle types are currently investigated for advanced ocular treatment due to improved drug retention times, higher bioavailability and better biocompatibility. Yet, comparative studies of both physicochemical and toxicological performance of these novel drug delivery systems are still rare. Herein, poly(L-lactic acid)- and poly(ε-caprolactone)-based micro- and nanoparticles were loaded with prednisolone as a model drug. The physicochemical properties of the particles were varied with respect to their hydrophilicity and size as well as their charge and the effect on prednisolone release was evaluated. The particle biocompatibility was assessed by a two-tier testing strategy, combining the EpiOcularTM eye irritation test and bovine corneal opacity and permeability assay. The biodegradable polyelectrolyte corona on the particles' surface determined the surface charge and the release rate, enabling prednisolone release for at least 30 days. Thereby, the prednisolone release process was mainly governed by molecular diffusion. Finally, the developed particle formulations were found to be nontoxic in the tested range of concentrations.
AB - A plethora of micro- and nanoparticle types are currently investigated for advanced ocular treatment due to improved drug retention times, higher bioavailability and better biocompatibility. Yet, comparative studies of both physicochemical and toxicological performance of these novel drug delivery systems are still rare. Herein, poly(L-lactic acid)- and poly(ε-caprolactone)-based micro- and nanoparticles were loaded with prednisolone as a model drug. The physicochemical properties of the particles were varied with respect to their hydrophilicity and size as well as their charge and the effect on prednisolone release was evaluated. The particle biocompatibility was assessed by a two-tier testing strategy, combining the EpiOcularTM eye irritation test and bovine corneal opacity and permeability assay. The biodegradable polyelectrolyte corona on the particles' surface determined the surface charge and the release rate, enabling prednisolone release for at least 30 days. Thereby, the prednisolone release process was mainly governed by molecular diffusion. Finally, the developed particle formulations were found to be nontoxic in the tested range of concentrations.
KW - поли(капролактон), поли(лактид), полимернглаз,
KW - ые наночастицы, альтернативные методы для тестирования на животных, биосовместимость, заболевания
KW - poly(ε-caprolactone)
KW - poly(L-lactide)
KW - polymeric nanoparticle
KW - alternative methods to animal testing
KW - biocompatibility
KW - eye diseases
KW - irritation
KW - ocular drug delivery
KW - Polymeric nanoparticle
KW - Poly(L-lactide)
KW - Ocular drug delivery
KW - Alternative methods to animal testing
KW - Poly(ε-caprolactone)
KW - Biocompatibility
KW - Eye diseases
KW - Irritation
UR - https://pubmed.ncbi.nlm.nih.gov/34072016/
UR - https://www.mdpi.com/1999-4923/13/6/801
UR - http://www.scopus.com/inward/record.url?scp=85107760559&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics13060801
DO - 10.3390/pharmaceutics13060801
M3 - Article
VL - 13
JO - Pharmaceutics
JF - Pharmaceutics
SN - 1999-4923
IS - 6
M1 - 801
ER -
ID: 77175964